Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Insider Sells 4,618 Shares of Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) insider Neil Gallagher sold 4,618 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares of the company's stock, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Syndax Pharmaceuticals Price Performance

NASDAQ:SNDX traded down $0.16 during trading hours on Friday, reaching $14.92. The company had a trading volume of 1,304,942 shares, compared to its average volume of 2,238,445. Syndax Pharmaceuticals, Inc. has a 1-year low of $12.06 and a 1-year high of $25.34. The firm has a market cap of $1.27 billion, a PE ratio of -4.11 and a beta of 0.90. The business's 50 day moving average price is $13.88 and its 200-day moving average price is $17.11.

Analyst Upgrades and Downgrades

SNDX has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an "overweight" rating in a report on Thursday, November 21st. StockNews.com downgraded Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, November 23rd. UBS Group initiated coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a "buy" rating and a $37.00 target price for the company. The Goldman Sachs Group lifted their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $36.20.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of SNDX. R Squared Ltd acquired a new position in Syndax Pharmaceuticals in the fourth quarter valued at approximately $26,000. Values First Advisors Inc. purchased a new stake in shares of Syndax Pharmaceuticals in the third quarter valued at approximately $30,000. Quantbot Technologies LP purchased a new stake in shares of Syndax Pharmaceuticals in the third quarter valued at approximately $49,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock valued at $58,000 after buying an additional 541 shares in the last quarter. Finally, Virtus ETF Advisers LLC increased its position in shares of Syndax Pharmaceuticals by 18.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after buying an additional 827 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).